IDE849
IDEAYA and Hengrui’s DLL3 ADC IDE849 Shows Promising Phase 1 Results at WCLC 2025
IDEAYA and Hengrui’s IDE849 (SHR-4849) showed strong Phase 1 efficacy and manageable safety in relapsed/refractory SCLC at WCLC 2025. This report covers trial outcomes, CNS activity, dosing, licensing, regulatory status, and the DLL3 competitive landscape.